The incidence increases 20 points after the weekend to 132 cases

The incidence continues with its upward trend and after the weekend stands at 132.19 cases per 100,000 inhabitants, 20 points more than on Friday, when 111.95 cases were registered. Since November 2, when 49.03 cases were reported, the incidence curve has not stopped rising, although experts point out that incidence is not the only indicator to take into account to know the epidemiological situation, and it is convenient analyze the level of saturation in hospitals. For now, hospital data does not register a large increase, although admissions from COVID patients do progressively increase.

The Ministry of Health has reported 15,875 infections after the weekend, while last Monday 9,798 positives were registered since Friday. In total, 5,096,538 people have been infected with the coronavirus.

In addition, 22 people have died since Friday from COVID-19. On Friday of last week, Health reported 43 deaths from the disease, and now the number of deaths since the coronavirus pandemic began already stands at 87,832.

More than half of those over 70 already have the booster dose against COVID-19

Spain advances in the rate of vaccination against COVID-19. Specifically, 90.8% of the target population, which enters the vaccination strategy, has at least one anti-COVID puncture, 80.6% of the total Spanish population. Regarding the complete regimen, 89.1% of the target population already have both doses of the vaccine against COVID-19, the complete regimen.

In addition, more than half (50.7%) of those over 70 years of age already have the booster dose or the third anti-COVID dose. In total, 3,610,960 people have this extra puncture in Spain.

By age, 84% of people between 12 and 19 years old already have the complete guideline against COVID-19, while people between 30 and 39 years old are still the group with the fewest vaccines administered: 77.1% of those People in this age group have both doses of the vaccine.

Source: Ministry of Health (data updated to )

New antivirals anticipate a different stage of the pandemic

During most of the pandemic, the improvement in the survival of COVID-19 patients has depended mainly on progress in life support measures and anti-inflammatory treatments that prevented the onset of complications triggered by the disease, such as an inflammatory response extreme.

Thus, it was found that medications such as corticosteroids (among them, dexamethasone, hydrocortisone or methylprednisolone) or inhibitors of pro-inflammatory molecules (anakinra, tocilizumab and baricitinib) could limit an uncontrolled reaction of the immune system and reduce the duration of mechanical ventilation and mortality in moderate and severe patients. In other words, the most useful drugs during much of the pandemic have been those that did not have antiviral effects against SARS-CoV-2.

During the course of this health crisis, many promising drugs have failed miserably against the coronavirus: hydroxychloroquine, ivermectin, antivirals used against HIV, antibiotics, interferon beta-1a, convalescent plasma … Only the antiviral remdesivir achieved authorization from the European Medicines Agency (EMA) in June 2020, but its alleged effectiveness has been surrounded by controversy, with the WHO publicly advising against its use due to negative results in its large SOLIDARITY clinical trial.

Source: – by

*The article has been translated based on the content of – by If there is any problem regarding the content, copyright, please leave a report below the article. We will try to process as quickly as possible to protect the rights of the author. Thank you very much!

*We just want readers to access information more quickly and easily with other multilingual content, instead of information only available in a certain language.

*We always respect the copyright of the content of the author and always include the original link of the source article.If the author disagrees, just leave the report below the article, the article will be edited or deleted at the request of the author. Thanks very much! Best regards!